gutsandgrowth

Pediatric Data for Mirkizumab –SHINE-1 Trial March 5, 2026 - (0)
Briefly noted: Jess L et al. The Lancet Gastroenterology & Hepatology 2025; 11: 100 – 109. Efficacy and safety of mirikizumab in paediatric participants with moderately-to-severely active ulcerative colitis (SHINE-1): a multicentre, open-label, non-randomised phase 2 trial Background: Mirikizumab, a immunoglobulin G4 monoclonal antibody, targets the p19 subunit of IL-23, with demonstrated efficacy and safety […]
Health Insurance Improves Survival and Outcomes in Patients with Liver Disease March 4, 2026 - (0)
Use of Neostigmine as Adjunct for Manual Disimpaction March 3, 2026 - (0)
Why Are Kids in U.S. Picky Eaters? March 2, 2026 - (0)
The Lancet Cover: Robert F Kennedy Jr: 1 year of failure March 1, 2026 - (0)

Mobile Site | Full Site